11:51 AM EST, 02/18/2025 (MT Newswires) -- Avalon GloboCare ( ALBT ) said Tuesday it received a notice of allowance from the China National Intellectual Property Administration for its patent application covering a technology designed to "enhance" the expansion, manufacturing, survival, and efficacy of chimeric antigen receptor, or CAR-T and CAR-natural killer cells.

The company said it co-developed the patent with Hong Kong-based Arbele.

Avalon GloboCare ( ALBT ) shares were up 7.3% in recent trading.

Price: 3.96, Change: +0.27, Percent Change: +7.32